Tiffany A. Traina, MD

In the program's closing segment, the panel shares practical pearls and reflections for clinicians.

The panel explores the rationale and emerging data for combining ADCs with immunotherapy and other targeted agents.

The panel discusses the notably low treatment discontinuation rates seen with ADCs in both pivotal trials compared with chemotherapy, and whether these reassuring numbers translate to real-world practice.

The panel reviews the distinct adverse event profile associated with datopotamab deruxtecan, moving from least to most common.

The panel takes a deeper look at neutropenia, one of the adverse events of special interest with sacituzumab govitecan.

The panel addresses one of the field's most pressing practical questions: what to offer after a first-line ADC, acknowledging that no prospective data yet exist to guide the decision.

The panel explores how to assign value to different trial endpoints in an aggressive disease, discussing overall survival as the gold standard while considering how crossover and confounding factors complicate its interpretation, and where PFS2 fits as a measure that reflects benefit across lines of therapy.

With both pivotal trials reviewed, the panel discusses how to reconcile the data when counseling an individual patient.

The panel reviews the TROPION-Breast02 findings, offering equipoise alongside the prior discussion of ASCENT-03.

The panel takes a closer look at ASCENT-03, framing it as a study designed to test whether a TROP2-directed ADC could serve as a first-line alternative to chemotherapy.

The panel turns to the design of two pivotal first-line trials, framing the discussion not as a head-to-head comparison but as a way to inform patient selection in clinic.

The panel addresses one of the more difficult challenges in metastatic TNBC: central nervous system involvement.

The panel discusses the rationale for using effective agents in the first-line metastatic setting rather than reserving them for later lines, considering the disease's aggressive course and limited expected survival alongside the trajectories seen in other breast cancer subtypes.

The panel reviews how the metastatic TNBC treatment paradigm has evolved, tracing TROP2-directed ADCs from later-line use into the first-line setting.

The panel grounds the discussion in the biology and natural history of metastatic triple-negative breast cancer, framing it as a high-proliferation subtype prone to rapid resistance, in which the first-line setting offers an important opportunity to influence outcomes. Panelists outline a biomarker-driven treatment algorithm stratified by PD-L1 status, germline BRCA status, and prior early-stage therapy, touching on immune checkpoint inhibition, PARP inhibitors, platinum-based chemotherapy, and the role of antibody-drug conjugates across lines of therapy.

Tiffany Traina, MD, FASCO, highlights results from the phase 3 TROPION-Breast02 trial showing that datopotamab deruxtecan significantly improved progression-free and overall survival versus chemotherapy in patients with previously untreated triple-negative breast cancer who were not eligible for immunotherapy.

Key opinion leaders anticipate future developments in HER2-positive breast cancer, and on the potential for translating therapeutic advances from the metastatic landscape into early-stage disease management.

Medical experts delve into the challenges of brain metastases in HER2-positive breast cancer, exploring local therapies for targeting central nervous system metastases and emphasizing the crucial role of multidisciplinary tumor boards, collaboration with colleagues, and referrals to specialized providers in optimizing patient outcomes.

Key opinion leaders revisit the HER2CLIMB trial, providing an in-depth analysis of the latest updates and their implications for the management of HER2-positive metastatic breast cancer.

Vijayakrishna Gadi, MD, PhD, presents the case of a 54-year-old woman with HER2-positive metastatic breast cancer exhibiting bone, liver, and brain lesions, and key opinion leaders share their perspectives on the most appropriate treatment approaches tailored to the patient's specific disease characteristics and metastatic sites.

Vijayakrishna Gadi, MD, PhD, shares his insights on managing patients with HER2-positive metastatic breast cancer who have progressed on second and third-line treatments, stressing the potential benefits of incorporating small molecules, tyrosine kinase inhibitors (TKIs), chemotherapy, and enrolling patients in clinical trials to optimize outcomes.

Tiffany A. Traina, MD, addresses adverse event monitoring and the range of adverse events patients may experience with front-line treatments for HER2-positive metastatic breast cancer, particularly highlighting alopecia and diarrhea as common side effects.

Key opinion leaders explore various therapeutic options for later-line treatment of HER2-positive metastatic breast cancer, emphasizing the significance of the HER2CLIMB and CLEOPATRA trials, while also drawing comparisons to real-world data to inform clinical decision-making.

Tiffany A. Traina, MD, presents a patient case involving a woman diagnosed with HR-negative, HER2 3+ invasive ductal adenocarcinoma and elaborates on the clinical management approaches employed in her treatment sequencing.

Heather McArthur, MD, emphasizes the influence of recent and ongoing clinical trials, specifically DESTINY-Breast09 and HER2CLIMB-05, in steering the treatment paradigm in 1st-line HER2-positive metastatic breast cancer.

Medical experts examine the current standards of care and successive lines of treatment for HER2-positive metastatic breast cancer, while also addressing the challenges encountered in managing this complex disease.

Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, underscore the importance of testing all early-stage and breast cancer patients for HER2 positivity to inform and guide optimal therapeutic decision-making.

Before closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.

Panelists focus on clinical trial data driving use of novel agents in the setting of HER2-low breast cancer and consider how they might select specific therapies.

Comprehensive insight on the novel treatment strategies available for patients diagnosed with HER2-low breast cancer.